Cell cycle checkpoint inhibition

Cell cycle checkpoint inhibition refers to the pharmacological targeting of regulatory kinases—most notably CHK1, CHK2, WEE1, ATR, ATM, and certain cyclin-dependent kinases—that normally stop cell cycle progression in the presence of DNA damage or incomplete replication. Inhibiting these proteins impairs the cell’s ability to pause for DNA repair, selectively sensitizing tumor cells (often p53-deficient) to DNA-damaging therapies by driving them through the cycle with unrepaired DNA, leading to cell death. Drugs exploiting this strategy are being developed as anti-cancer agents, frequently in combination with chemotherapy or radiation. This is a process or strategy, not a single protein/receptor, and should be mapped to the respective molecular targets for structured data. The key targets include Checkpoint kinase 1 (CHK1), Checkpoint kinase 2 (CHK2), WEE1 G2 checkpoint kinase, ATR, ATM, and relevant cyclin-dependent kinases (CDKs).

Other names

Cell cycle checkpoint kinase inhibitionCell cycle checkpoint abrogationCheckpoint inhibition (cell cycle, not immune)Checkpoint kinase inhibition

Inhibition of cell cycle checkpoint kinases leads to abrogation of cell cycle arrest after DNA damage, forcing cells through the cycle and increasing sensitivity to DNA-damaging agents (such as chemotherapy or radiation). Preventing effective DNA repair results in mitotic catastrophe or apoptosis, especially in cancer cells with impaired p53 pathways.